MeSH tree: D23.050.865.450
mRNA vaccines developed against the spike glycoprotein of severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2), displayed remarkable efficiency in combating coronavirus 19 (COVID-19). These vaccines work by triggering ...
Mar 8, 2024
0
50
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen have examined a man who has received more than 200 vaccinations against COVID-19. They learned of his case via newspaper ...
Mar 5, 2024
0
220
The success of mRNA vaccines against COVID-19 has unleashed a flood of interest in using the technology to create more vaccines and treatments for everything from rare diseases and infections to cancer.
Feb 28, 2024
0
61
A research team at Freie Universität Berlin has conducted a comprehensive comparison of the efficacy of a mucosal, replication-competent but fully attenuated virus vaccine, sCPD9-ΔFCS, with the monovalent mRNA vaccine BNT162b2 ...
Feb 27, 2024
0
49
The COVID-19 pandemic spurred the rapid development of different vaccines, including the messenger RNA (mRNA)-1273 vaccine produced by Moderna.
Feb 16, 2024
1
73
The COVID-19 pandemic was an especially harrowing time for pregnant people and new parents.
Jan 29, 2024
0
39
A recent study has revealed the effectiveness of COVID-19 vaccines in preventing long COVID.
Jan 12, 2024
0
77
Children and adolescents who received one of the main COVID-19 vaccines were significantly protected from the illness and showed no increased signs of cardiac complications compared to young people who were not vaccinated, ...
Jan 8, 2024
0
83
mRNA, a type of genetic material that provides the instructions your cells need in order to make proteins, used to be a term mainly used by scientists. But since COVID arrived, many of us are now familiar with it thanks to ...
Dec 19, 2023
0
55
Pfizer announced Tuesday that it expects to complete this week its $43 billion acquisition of cancer-focused biotech company Seagen after clearing key regulatory hurdles.
Dec 12, 2023
0
80
